- Home
- DAVA vs SLP Comparison
DAVA vs SLP Comparison
Compare DAVA & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | SLP |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 293.5M |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DAVA | SLP |
|---|---|---|
| Price | $4.65 | $12.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $14.57 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 524.0K | 387.5K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $59,577,000.00 |
| Revenue This Year | N/A | $2.64 |
| Revenue Next Year | $4.26 | $6.01 |
| P/E Ratio | ★ $20.02 | $404.00 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $4.38 | $11.16 |
| 52 Week High | $24.40 | $36.43 |
Technical Indicators
Market Signals| Indicator | DAVA | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 30.60 |
| Support Level | N/A | N/A |
| Resistance Level | $7.04 | $13.84 |
| Average True Range (ATR) | 0.37 | 0.74 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 19.34 | 30.80 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.